文献速递免疫规划

脂质体TLR7配体多次鼻内加强的异源初免-加强方案增强疫苗免疫原性

Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand.
PubMed 文献 · Vaccine · 2025-10-08

研究开发了脂质体纳米颗粒Lipo-1V270(合成TLR7激动剂1V270的脂质体制剂),在小鼠模型中评估肌内和鼻内途径的免疫原性,包括以MPLA佐剂灭活甲型流感病毒肌内初免后、Lipo-1V270鼻内加强的异源初免-加强方案;结果显示该方案可增强黏膜和全身免疫应答,且加强后7天内未引起显著体重下降。

要点

  • Lipo-1V270体外固有免疫刺激效力较未制剂化1V270减弱。
  • 与IIAV共给予Lipo-1V270显著增强抗原特异性IgG1和IgG2a应答。
  • MPLA佐剂IIAV肌内初免后Lipo-1V270鼻内加强,诱导鼻洗液HA特异性IgA和IgG及脾T细胞应答。

核心结论

  • 异源初免-加强方案中鼻内给予Lipo-1V270可有效增强针对流感病毒感染的黏膜免疫,固有免疫介导的不良反应谱可接受。
  • 该策略可能适用于其他呼吸道传染病的疫苗。

研究设计与样本

  • 研究开发了Lipo-1V270,即使用1,2-二油酰-sn-甘油-3-磷酸胆碱(DOPC)和胆固醇制备的合成TLR7激动剂1V270脂质体纳米颗粒制剂,用于黏膜疫苗递送。
  • 采用小鼠模型评估体外免疫刺激和体内免疫原性,途径包括肌内和鼻内,并纳入以单磷酸酰脂质A(MPLA)佐剂的灭活甲型流感病毒[A/California/04/2009 (H1N1)pdm09]初免的异源初免-加强方案。

主要发现

  • 体外分析显示Lipo-1V270的固有免疫刺激效力较未制剂化1V270减弱。
  • 体内与IIAV共给予Lipo-1V270显著增强抗原特异性IgG1和IgG2a应答。
  • 以MPLA佐剂IIAV肌内初免后、Lipo-1V270鼻内加强,在鼻洗液中诱导强烈的流感血凝素(HA)特异性黏膜IgA和IgG应答。
  • 该异源初免-加强方案还诱导强烈的脾T细胞应答及鼻洗液HA特异性IgG和IgA抗体,免疫小鼠加强后7天内未出现显著体重下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite the clinical efficacy of current intramuscular influenza vaccines in reducing the severity of seasonal infection, they exhibit limited induction of mucosal immunity, which is essential for preventing viral transmission. In addition, intranasal vaccination can induce superior mucosal immunity, enhancing clinical efficacy and reducing transmission, and its self-boosting potential may improve coverage in older adults and those with mobility limitations. METHODS: We developed Lipo-1V270, a liposomal nanoparticle formulation of the synthetic TLR7 agonist 1V270 using 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and cholesterol for mucosal vaccine delivery. In vitro immune stimulation and in vivo immunogenicity were evaluated using intramuscular and intranasal routes in mouse models, including a heterologous prime-boost regimen with inactivated influenza A virus [IIAV, A/California/04/2009 (H1N1)pdm09] adjuvanted monophosphoryl lipid A (MPLA) priming. RESULTS: In vitro analysis showed that Lipo-1V270 exhibited attenuated innate immune potency compared to unformulated 1V270. However, in vivo co-administration of Lipo-1V270 with IIAV significantly enhanced antigen-specific IgG1 and IgG2a responses. Subsequently, intranasal boosting with Lipo-1V270, following intramuscular priming with IIAV adjuvanted with MPLA - a component included in FDA-approved vaccines - elicited robust influenza-hemagglutinin (HA)-specific mucosal IgA and IgG responses in nasal wash. This heterologous prime-boost regimen also induced strong splenic T-cell responses and HA-specific IgG and IgA antibodies in nasal wash without causing significant weight loss for 7 days post-boost in immunized mice. CONCLUSIONS: Intranasal administration of Lipo-1V270 in a heterologous prime-boost vaccination regimen effectively enhances mucosal immunity against influenza virus infection, with an acceptable innate immune-mediated adverse effects profile. This strategy may be applicable to vaccines against other respiratory infectious diseases.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hayashi T, Yao S, Sato-Kaneko F, et al. Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand. Vaccine. 2025. PMID: 41067087. doi:10.1016/j.vaccine.2025.127778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。